Sourcefire, Inc. (NASDAQ: FIRE), Gladstone Commercial Corp (NASDAQ: GOOD), Lazard Ltd (NYSE: LAZ), LHC Group, Inc. (NASDAQ: LHCG) and Lifepoint Hospitals (NASDAQ: LPNT) upgraded by analysts.
Sourcefire, Inc. (FIRE) was upgraded by UBS AG (NYSE:UBS) from a “Neutral” rating to a “Buy” rating. They have a price target of $32.00 on the company.
Gladstone Commercial Corp. (GOOD) was upgraded by Hilliard Lyons from a “Neutral” rating to a “Buy” rating. They have a price target of $19.00 on the company.
Lazard Ltd (LAZ) was upgraded by Citigroup (NYSE:C) from a “Hold” rating to a “Buy” rating. They have a price target of $42.00 on the company.
LHC Group, Inc. (LHCG) was upgraded by Jefferies (NYSE:JEF) from an “Underperform” rating to a “Hold” rating. They have a price target of $20.00 on the company, up from $19.00.
Lifepoint Hospitals (LPNT) was upgraded by Leerink from an “Underperform” rating to a “Market Perform” rating.
Showing posts with label LHC Group. Show all posts
Showing posts with label LHC Group. Show all posts
Friday, August 5, 2011
Sotheby’s (BID) (WXS) (AZN) (S) (LHCG) (EMC) Upgraded
Sotheby’s (NYSE: BID), Wright Express Co. (NYSE: WXS), AstraZeneca (NYSE: AZN), Sprint Nextel (NYSE: S), LHC Group, Inc. (NASDAQ: LHCG) and EMC Corp. (NYSE: EMC) upgraded by analysts.
Wright Express Co. (WXS) was upgraded by Morgan Keegan from a “Market Perform” rating to an “Outperform” rating. They have a price target of $58.00 on the company.
AstraZeneca (AZN) was upgraded by Jefferies (NYSE:JEF) from an “Underperform” rating to a “Hold” rating.
Sotheby’s (BID) was upgraded by Craig Hallum from a “Hold” rating to a “Buy” rating. They have a price target of $54.00 on the company.
Sprint Nextel (S) was upgraded by Stifel Nicolaus from a “Sell” rating to a “Hold” rating.
LHC Group, Inc. (LHCG) was upgraded by Robert W. Baird from an “Underperform” rating to a “Neutral” rating. They have a price target of $20.00 on the company, up from $17.00.
EMC Corp. (EMC) was upgraded by Collins Stewart from a “Neutral” rating to a “Buy” rating. They have a price target of $32.00 on the company, up from $30.00.
Wright Express Co. (WXS) was upgraded by Morgan Keegan from a “Market Perform” rating to an “Outperform” rating. They have a price target of $58.00 on the company.
AstraZeneca (AZN) was upgraded by Jefferies (NYSE:JEF) from an “Underperform” rating to a “Hold” rating.
Sotheby’s (BID) was upgraded by Craig Hallum from a “Hold” rating to a “Buy” rating. They have a price target of $54.00 on the company.
Sprint Nextel (S) was upgraded by Stifel Nicolaus from a “Sell” rating to a “Hold” rating.
LHC Group, Inc. (LHCG) was upgraded by Robert W. Baird from an “Underperform” rating to a “Neutral” rating. They have a price target of $20.00 on the company, up from $17.00.
EMC Corp. (EMC) was upgraded by Collins Stewart from a “Neutral” rating to a “Buy” rating. They have a price target of $32.00 on the company, up from $30.00.
Wednesday, January 19, 2011
LHC Group (NASDAQ:LHCG) Challenged by Pricing Environment
LHC Group (NASDAQ:LHCG) remains one of the stronger post–acute care companies, as they have a strong exposure to the rural market, but going forward they will be challenged by the current pricing market, along with uncertainty concerning regulatory scrutiny the overall industry is receiving.
FBR says, "LHC Group is one of the better positioned post–acute care companies due to its higher level of rural exposure; that positioning, however, is reflected in the premium valuation that LHCG shares receive relative to peers. While the company’s JV strategy and M&A activity add to its ability to grow volumes beyond that of the overall market, we still expect LHC Group to be challenged by the pricing environment. The company also has overhangs that are similar to its peers such as the SEC/SFC investigations, potential for rebasing in 2014, and increased regulatory scrutiny. But, we also believe that the company is in the midst of adopting point-of-care solutions, which could increase the efficiency and profitability of the company over the long term."
FBR Capital reiterates a "Market Perform" rating on LHC Group (LHCG), which closed Tuesday at $28.94, up $0.21, or 0.73 percent. FBR raised their price target on LHC from $25 to $28.
FBR says, "LHC Group is one of the better positioned post–acute care companies due to its higher level of rural exposure; that positioning, however, is reflected in the premium valuation that LHCG shares receive relative to peers. While the company’s JV strategy and M&A activity add to its ability to grow volumes beyond that of the overall market, we still expect LHC Group to be challenged by the pricing environment. The company also has overhangs that are similar to its peers such as the SEC/SFC investigations, potential for rebasing in 2014, and increased regulatory scrutiny. But, we also believe that the company is in the midst of adopting point-of-care solutions, which could increase the efficiency and profitability of the company over the long term."
FBR Capital reiterates a "Market Perform" rating on LHC Group (LHCG), which closed Tuesday at $28.94, up $0.21, or 0.73 percent. FBR raised their price target on LHC from $25 to $28.
Tuesday, December 7, 2010
LHC Group (NASDAQ:LHCG) EPS Estimates Lowered by Jefferies (NYSE:JEF)
Saying the downwardly revised EPS estimate on LHC Group (NASDAQ:LHCG) is strictly technical and related to reimbursements, Jefferies (NYSE:JEF) lowered EPS for full year 2010.
They explained, "Today's revision to our FY10 EPS estimate is a strictly technical, reimbursement-related one and does not reflect weakening fundamentals at LHCG. On the contrary, we are raising our FY11 EPS estimate to reflect likely prospects of improved margins from drop sites and cost efficiencies."
Full year revenue, and EBITDA estimates were lowered to $2.72, $633.2M, and $88.4 from $2.78, $635M, and $90.2. Also changed were their estimates for full year 11 to $2.57, $648.3M, and $85.5 from $2.54, $686.3M, and $84.6.
Jefferies reiterates their "Buy" rating on LHC, which closed Monday at $24.25, losing $0.49, or 1.98 percent. They have a price target of $32 on the company.
They explained, "Today's revision to our FY10 EPS estimate is a strictly technical, reimbursement-related one and does not reflect weakening fundamentals at LHCG. On the contrary, we are raising our FY11 EPS estimate to reflect likely prospects of improved margins from drop sites and cost efficiencies."
Full year revenue, and EBITDA estimates were lowered to $2.72, $633.2M, and $88.4 from $2.78, $635M, and $90.2. Also changed were their estimates for full year 11 to $2.57, $648.3M, and $85.5 from $2.54, $686.3M, and $84.6.
Jefferies reiterates their "Buy" rating on LHC, which closed Monday at $24.25, losing $0.49, or 1.98 percent. They have a price target of $32 on the company.
Subscribe to:
Posts (Atom)